You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

315 Results
Document
Mar 2022
Document
Mar 2022
Document
Mar 2022
Document
Apr 2022
Document
Apr 2022
Document
Apr 2022
Document
Apr 2022
Guidelines and Advice
Status: Current
ID: PET 2021-2
Jun 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
riTUXimab (PDRP prior authorization),
etoposide,
ifosfamide,
mesna,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2022
Drug
Other Name(s): Rozlytrek®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2024
Document
Aug 2022
Document
Sep 2022

Pages